GLMD News and Press, Galmed Pharmaceuticals Ltd. From 08/04/22

Galmed press release ( NASDAQ: GLMD ): Q2 GAAP EPS of -$0.15 beats by $0.09 . Cash and cash equivalents, restricted cash and marketable debt securities totaled $22.5 million as of June 30, 2022, compared to $34.9 million at December 31, 2021. For further details ...

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results PR Newswire TEL AVIV, Israel , Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage bio...

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model PR Newswire Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (IBD) Data reinforcing the expansio...

Galmed Pharma (NASDAQ:GLMD) said on Friday it had received a letter from the Nasdaq saying that the Company was not in compliance with the minimum bid price requirement for continued listing, which requires listed securities to maintain a minimum bid price of $1.00 per share. The Company has ...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel , June 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical ...

Galmed Pharmaceuticals (NASDAQ:GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without a price target. The company had reported Q1 GAAP EPS of -$0.24, beats by $0.08. H.C. Wainwrigh...

Galmed press release (NASDAQ:GLMD): Q1 GAAP EPS of -$0.24 beats by $0.08. Cash and cash equivalents, restricted cash and marketable debt securities totaled $28.9 million as of March 31,2022, compared to $34.9 million at December 31, 2021. Shares +12% For further details see: Galmed GAAP...

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results PR Newswire TEL AVIV, Israel , May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liv...

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects PR Newswire Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known...

Galmed Pharma (NASDAQ:GLMD) is trading lower for the second straight session after H.C. Wainwright downgraded the Israel-based biotech to Neutral on Tuesday, citing, among other things, uncertainty in its research into liver disease, non-alcoholic steato-hepatitis (NASH). Commenting on a regi...